Kyowa Hakko’s IMMUSE™ Postbiotic Wins Inaugural “Microbiome Modulation” Industry Award

Kyowa Hakko USA is thrilled to announce that our groundbreaking product, IMMUSE™ postbiotic for immune health, has been honored as the inaugural recipient of the the Ingredient of the Year: Microbiome Modulation category in the esteemed annual awards by NutraIngredients-USA.

IMMUSE™ is a clinically researched Lactococcus lactis strain Plasma (LC-Plasma) that uniquely activates the immune system and plasmacytoid dendritic cells (pDCs) to support healthy days*. Thirty published studies, including 15 human trials, support IMMUSE™’s novel mechanism of action.

“In a very competitive category with lots of established ingredients, Kyowa’s IMMUSE™ Lactococcus lactis strain Plasma stood out as an interesting postbiotic product with a novel approach to supporting immune health,” said Stephen Daniells, PhD, Editor-in-Chief of NutraIngredients-USA. “The ingredient is backed by good science, including a clinical trial with school children. Despite only being on the U.S. market for two years, IMMUSE™ Lactococcus lactis strain Plasma is already used in numerous consumer products.”

The pDC, a rare type of immune cell, functions as a key leader of the immune system and has been shown to activate other cells pivotal to immune support such as NK, Killer-T, Helper-T, and B cells for a more comprehensive approach to immune support*.

“We are so honored that NutraIngredients-USA values the rigorous clinical testing we’ve conducted to ensure IMMUSE™’s efficacy,” said Karen Todd, MBA, RD, Vice President of Global Brand Marketing, Kyowa Hakko USA, Inc. “This is yet another testament to how critical it is that branded ingredients are clinically researched – that’s how we can prove that these products do what they say they do and earn consumers’ trust.”

Kyowa Hakko’s parent company, Kirin Holdings Co., Ltd. discovered IMMUSE™’s unique mechanism of action.

Due to its stable nature, long shelf life, and flexible formulation, IMMUSE™ can be used in a variety of applications, from powders and capsules to functional beverages. To learn more about IMMUSE™ or inquire about using it in a future formulation, visit Kyowa Hakko July 17-19 at IFT FIRST in booth S0233 or on its website.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

**IMMUSE™ is a clinically researched lactic acid bacteria developed by Kirin Holdings Co., Ltd.

About Kyowa Hakko USA
Kyowa Hakko USA is the North & South American office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food products. For more information, visit